February 9, 2016
As the Japan Atherosclerosis Society has launched discussions to revise the current guidelines for the prevention of atherosclerosis, physicians have high hopes for PCSK9 inhibitors and selective PPARα modulators as new therapeutic modalities for hyperlipidemia. At a Tokyo symposium held...read more